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ABSTRACT
This study analysed the occurrence of carbapenem resistance among Acinetobacter baumannii isolates
from a tertiary-care hospital in Poland, together with the molecular epidemiology of these isolates and
the risk-factors for their acquisition and possible nosocomial spread. The medical charts of 21 patients
with Acinetobacter infection or colonisation revealed that A. baumannii isolates were obtained most
frequently from intensive care unit and surgical patients (particularly those receiving transplantation
surgery). First isolation occurred, on average, on day 21 following admission (range 5–45 days).
Infection with Acinetobacter contributed directly to the death of seven patients. Several patients were
infected with more than one strain, and molecular typing revealed the co-circulation of three
predominant clones, of which two belonged to the Acinetobacter lineages designated as European clones
I and II. All three clones encoded an OXA-51-type carbapenemase, but were negative for carbapenemases
belonging to the OXA-23, OXA-24 and OXA-58 families. The OXA-51 gene was found in both resistant
and susceptible isolates, and was not associated directly with carbapenem resistance. Etests with
imipenem and imipenem plus EDTA indicated production of a metallo-b-lactamase (MBL) in
carbapenem-resistant isolates. PCRs for IMP-type MBLs were negative, but PCR using consensus
primers for VIM-type MBLs were positive for carbapenem-resistant isolates belonging to the European
clone II lineage. The occurrence of a VIM-type MBL in association with one of the epidemic lineages of
A. baumannii is a cause for concern. Further studies are needed to evaluate possible inter-hospital spread
of resistant A. baumannii strains in Poland.
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INTRODUCTION
Bacteria of the genus Acinetobacter are non-fer-
menting Gram-negative bacilli that have emerged
as important multidrug-resistant pathogens [1].
Outbreaks of infection involving strains of Acine-
tobacter baumannii are being reported increasingly,
particularly among patients hospitalised in inten-
sive care units (ICUs), surgical units or burns
units [2–6]. Such outbreaks are difficult to control
and often result in multiresistant strains of
A. baumannii becoming endemic in hospitals.
Most recently, infections caused by multiresistant
strains of A. baumannii have achieved even great-
er prominence in Europe and the USA, following
the repatriation of military patients from the
ongoing conflict in Iraq [7–10].
Apart from being intrinsically resistant to cer-
tain classes of antibiotics, strains of Acinetobacter
can develop or acquire resistance easily to a wide
variety of antibacterial agents [11–13]. At present,
carbapenems are still used widely for treatment of
infections caused by A. baumannii [11,12]. How-
ever, resistance to carbapenems in this species is
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now reported increasingly worldwide [14],
prompting investigations into the use of colistin
for therapy of infections caused by otherwise pan-
resistant strains of Acinetobacter [15,16].
Published data concerning the frequency of
carbapenem resistance among clinical isolates of
Acinetobacter spp. from eastern and central Europe,
including Poland, are scarce. Fleischer et al. [17]
reported an increase in imipenem MICs for
A. baumannii isolates from ICU patients in Poland,
and a study of clinical isolates of Acinetobacter
spp. collected in Poland between 1995 and 2001
revealed a relatively low frequency of resistance,
4%, to carbapenems [18]. In contrast, a high
frequency of carbapenem resistance was reported
recently among Acinetobacter isolates from ICU
patients in a tertiary-care hospital in Warsaw [19].
The aims of the present study were therefore to
gain a further insight into the occurrence of
carbapenem-resistant and -susceptible Acinetob-
acter isolates in Poland by investigating isolates
from patients hospitalised in a tertiary-care hos-
pital in Warsaw to determine their molecular
epidemiological relationships and possible mech-
anisms of carbapenem resistance.
MATERIALS AND METHODS
Hospital setting and patients
The study was conducted between 2003 and 2005 in a 1140-bed
university-affiliated hospital in Warsaw, Poland. The hospital
contained 15 highly specialised wards (seven surgical wards
and eight internal medicine wards), as well as an ICU with
eight beds. In addition, specialised ICUs were contained
within different wards. The numbers of hospitalised patients
were 54 386 in 2003, 56 442 in 2004 and 59 444 in 2005,
corresponding to 346 586, 336 919 and 332 223 patient-days in
2003, 2004 and 2005, respectively. The numbers of outpatient
consultations were 195 548, 196 507 and 198 231 in 2003, 2004
and 2005, respectively. ICU occupancy amounted to 2261
patient-days in 2003, 2866 patient-days in 2004, and 2358
patient-days in 2005. The following data were recorded from
the medical charts that were available for analysis for 21
patients with A. baumannii infection or colonisation: age,
gender, number of patient-days in hospital, underlying dis-
eases or conditions, and clinical outcome.
Bacterial isolates
In total, 110 Acinetobacter isolates were recovered during the
period of the study, predominantly from blood, catheter tips,
aspirates, wound swabs, urine and intra-operative specimens.
Bacteria were cultured according to standard bacteriological
techniques and with an automated BacT ⁄Alert system
(bioMe´rieux, Marcy l’Etoile, France). Bacterial isolates were
identified initially by API and VITEK tests (bioMe´rieux).
Twenty-four isolates were selected randomly for detailed
retrospective study, and these were further confirmed as
A. baumannii by tRNA spacer fingerprinting [20].
Antimicrobial susceptibility testing
Susceptibility of the isolates to antibacterial agents was tested
initially by a disk-diffusion method, according to CLSI
(formerly NCCLS) recommendations [22], and with the VITEK
system (bioMe´rieux). For carbapenems, the diameters of the
inhibition zones were interpreted as: £13 mm, resistant;
14–15 mm, intermediate; and ‡16 mm, susceptible [21]. Resist-
ance of A. baumannii isolates to imipenem and ⁄ or meropenem
was verified by determination of MICs with Etests (AB
Biodisk, Solna, Sweden), using interpretation breakpoints of
£4 mg ⁄L as susceptible, 8 mg ⁄L as intermediately-susceptible,
and ‡16 mg ⁄L as resistant [22].
Consumption of antimicrobial agents
Consumption of antimicrobial agents was determined in terms
of the total number of defined daily doses (DDD) of the
antibacterial agents, and was expressed as DDD ⁄ 1000 patient-
days.
Molecular typing
The 24 randomly selected isolates were typed retrospectively
by molecular techniques, initially using DAF4 randomly
amplified polymorphic DNA analysis, as described by Grund-
mann et al. [23], and by pulsed-field gel electrophoresis of
ApaI-digested total chromosomal DNA, prepared as described
previously [24], in a CHEF DRII apparatus (Bio-Rad, Hemel
Hempstead, UK) at 200 V for 20 h at 14C, with a ramped
pulse of 5–13 s. Type strains of European clones I (RUH 2037),
II (RUH 134) and III (LUH 5875) were kindly supplied by
L. Dijkshoorn (LUMC, Leiden, The Netherlands).
Detection of carbapenem resistance genes
Multiplex PCRs for detection of the four major families of
OXA-type class D carbapenemases found in Acinetobacter spp.
were performed as described by Woodford et al. [25]. The
presence of metallo-b-lactamases (MBLs) was determined
using MBL Etests (AB Biodisk). PCRs for MBLs were
performed using primers and PCR conditions described
previously [26,27]. The VIM consensus primers were those
recommended by Poirel et al. [27].
RESULTS
Epidemiological data and antimicrobial
susceptibilities
Isolates of A. baumannii (n = 110) were obtained
from patients in various wards of the hospital
throughout the period 2003–2005. Molecular typing
of 24 randomly selected isolates from 22 patients
by DAF4 randomly amplified polymorphic DNA
analysis and ApaI macrorestriction pulsed-field
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gel electrophoresis revealed the co-circulation of
three predominant clones, designated types 1–3
(Table 1). The results obtained by randomly
amplified polymorphic DNA analysis and
pulsed-field gel electrophoresis were concordant.
Patients hospitalised in the ICU (10 ⁄ 22) and
surgical wards (10 ⁄ 22) predominated among the
group of patients analysed in detail (Table 1). The
mean age of these patients was 46.2 (range 20–69)
years, and there was a predominance of males
(13 ⁄ 22). The length of hospital stay ranged from
9 to >150 days. On average, Acinetobacter spp. was
first isolated 21 (range 5–45) days following
admission (Table 1). The antimicrobial suscepti-
bilities of the 24 selected isolates are shown in
Table 2; among these isolates were 15 that were
intermediately-susceptible or resistant to imipe-
nem, and 16 that were intermediately-susceptible
or resistant to meropenem.
Consumption of antimicrobial agents
Total antibiotic consumption in the hospital was
159 714.2 DDD in 2003, 161 889.9 DDD in 2004,
and 166 527.4 DDD in 2005 (460.8 DDD ⁄ 1000
patient-days, 480.5 DDD ⁄ 1000 patient-days and
501.3 DDD ⁄ 1000 patient-days, respectively). Con-
sumption of carbapenems throughout the entire
hospital amounted to 6999.0 DDD in 2003,
8742.0 DDD in 2004, and 9767.3 DDD in 2005.
Total antibiotic consumption in the ICU was
1365.94 DDD ⁄ 1000 patient-days in 2003, 1192.80
DDD ⁄ 1000 patient-days in 2004 and 1157.84
DDD ⁄ 1000 patient-days in 2005. Consumption of
carbapenems in the ICU amounted to 668.0 DDD
in 2003, 578.3 DDD in 2004, and 452.3 DDD in
2005.
Molecular typing and PCR analysis of
carbapenem resistance genes
As described above, molecular typing revealed
the co-circulation of three clones (types 1–3) and
one sporadic isolate (type 4) (Table 1). Direct
comparative analysis of typing profiles with those
of known strains revealed that type 1 belonged to
the ’European clone I’ lineage, while type 3
belonged to the ’European clone II’ lineage. The
’European clone III’ lineage was not represented
among the isolates studied. Carbapenem resist-
ance in the A. baumannii isolates was not associ-
ated with any particular molecular type, and
isolates susceptible or resistant to both imipenem
and meropenem were found within each type
(Table 2).
All three types were shown in multiplex PCRs
to carry a gene encoding an OXA-51-type enzyme
(353 bp), but were negative for genes encoding
enzymes belonging to the OXA-23 (501 bp), OXA-
24 (246 bp) and OXA-58 (599 bp) families. The
OXA-51-type enzyme did not appear to be asso-
ciated directly with carbapenem resistance, and
was found in both resistant and susceptible
isolates.
Etests with imipenem and imipenem plus
EDTA indicated the presence of an MBL in
resistant isolates. PCRs for IMP-type MBLs were
negative, but PCR using consensus primers for
VIM-type MBLs yielded a 510-bp product, as
predicted from the sequence analysed by Poirel
et al. [27], from resistant isolates belonging to
molecular type 3 (the European clone II lineage),
but not from the other molecular types represent-
ed among the isolates studied.
DISCUSSION
Bacteria of the genus Acinetobacter pose a threat to
hospitalised patients, as they may spread nosoco-
mially, while acquiring resistance to many groups
of antibacterial agents. The frequency of isolation
and variety of clones of these bacteria found in
clinical specimens in different countries vary
widely [1,12,28,29], but three widespread Euro-
pean lineages (’clones’) of A. baumannii have been
identified [30,31], with European clone I having
been reported previously in Poland [30]. Potential
risk-factors for colonisation or infection of
hospitalised patients with multidrug-resistant
Acinetobacter strains include length of ICU stay,
underlying diseases or conditions, exposure to
carbapenems or third-generation cephalosporins,
hospital size (>500 beds) and urinary catheterisa-
tion [29,32–34]. In the present study, isolation of
A. baumannii occurred most frequently among
ICU and surgical patients (particularly those
undergoing transplantation surgery) after a mean
hospital stay of 21 days. Infection with Acinetob-
acter contributed directly to the death of seven
patients, while a further four patients died of
other conditions, probably not related directly to
the Acinetobacter infection.
Emergence of carbapenem resistance among
strains of A. baumannii constitutes a major
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therapeutic problem and warrants epidemiologi-
cal and microbiological interventions [35]. Several
mechanisms of carbapenem resistance have been
described, including decreased outer-membrane
permeability caused by the loss or reduced
expression of porins, alterations in penicillin-
binding proteins, production of carbapenemases
and other b-lactamases, as well as over-expression
Table 1. Epidemiological profile of selected patients infected or colonised with Acinetobacter baumannii
Strain
no.
Molecular
typea
Age
(years) Gender
Material ⁄
specimen Ward
Length
of stay
(days)
Day of
isolation of
Acinetobacter Outcome Disease
B-1 1 41 F Catheter ICU 52 23 Died Pancreatic abscesses
after
cholecystectomy
B-2 2 41 M CSF ICU 65 23 Died Acute pancreatitis;
sepsis
B-3 3 55 M Catheter 4B 138 31 Recovered Ischaemia of the
lower limb;
implantation of an
aortic–femoral graft
B-4 4 69 M Catheter 6B 92 45 Diedb Pancreatic carcinoma
with metastases
B-5 2 36 M Wound 4B 29 18 Diedb Ischaemia of the
lower limb;
myocardial
infarction
B-6 2 55 F Aspirate ICU 10 7 Died Carcinoma of the
rectum; septic shock
B-7 2 Same
as B-2
Same
as B-2
Intubation
tube
Same
as B-2
Same
as B-2
13 Same
as B-2
Same as B-2
B-8 2 50 M Aspirate ICU 86 22 Died Cerebral
haemorrhage; sepsis
B-9 2 53 F Wound 3B 20 10 Recovered Necrotic
cholecystitis
B-10 3 NA M Blood 4D NA NA NA Haematological ⁄
oncology disease
B-11 2 60 F Catheter 4B 52 32 Recovered Intestinal
obstruction;
pneumonia
B-12 2 27 M CSF ICU 63 20 Recovered Multi-organ trauma
B-13 3 20 F Catheter ICU 9 8 Diedb Organ donor for
transplantations
B-14 1 55 M Catheter ICU 30 8 Recovered Cerebral trauma
B-15 3 50 M Wound 8B 10 6 Died Cerebral
haemorrhage;
pneumonia
B-16 2 47 F Aspirate 3B 50 44 Recovered Abdominal abscesses
after abdominal
surgery in another
hospital
B-17 3 43 M Intubation
tube
ICU 11 5 Diedb Haemorrhage from
gastrointestinal
tract; alcoholic
liver cirrhosis
B-18 2 36 F Aspirate ICU 61 33 Died Brain tumour
B-19 1 45 F Wound CS 125 8 Recovered Artificial heart
valve; pneumonia;
decubitus
B-20 2-like Same
as B-12
Same
as B-12
Wound Same
as B-12
Same
as B-12
13 Same
as B-12
Same
as B-12
B-21 3 33 M Wound ICU 55 34 Died Pancreatitis of
transplanted
pancreas (9 ⁄ 2005,
transplantation of
pancreas and kidney)
B-22 3 35 M Drainage
fluid
4B 44 30
after
Tx
Recovered Kidney transplant
recipient
B-23 3 50 M Drain 6B >150 17 Recovered Abscesses of
transplanted liver;
remains hospitalised
(3 ⁄ 2006)
B-24 2 69 F Urine 6D 63 29 Recovered Renal insufficiency;
peritoneal dialysis
3B, Department of gastrointestinal surgery; 4B, Department of vascular surgery and transplantation; 6B, Department of general surgery and liver transplantation; 8B,
Department of neurosurgery; ICU, intensive care unit; 4D, Department of haematology–oncology; 6D, Department of nephrology; CS, Department of cardiosurgery; NA, data
not available; CSF, cerebrospinal fluid.
aMolecular type 1 belongs to the European clone I lineage, and molecular type 3 belongs to the European clone II lineage.
bDeath not related directly to infection with Acinetobacter.
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of multidrug efflux pumps [14]. Data concerning
carbapenem resistance among Acinetobacter iso-
lates in Poland are scarce. No resistance to
carbapenems was detected among 32 clinical
Acinetobacter ICU isolates in Poland during
1997–2000 [36], but an increase in the imipenem
MICs for isolates from ICU patients has been
reported since 2000 [17,19]. Wroblewska et al. [19]
reported that the percentage of imipenem-resist-
ant strains of A. baumannii was particularly high
among blood isolates, amounting to c. 40% in two
ICUs.
Molecular typing of multidrug-resistant A. bau-
mannii is important to enable epidemiological
tracing of these strains. Although certain clones
show widespread dissemination [30,31], isolates
of A. baumannii from hospitals in the same coun-
try, or even from within a single hospital, may
show significant genetic diversity [28,29,37]. In
the present study, molecular typing revealed the
co-circulation of four different strains (types 1–4),
of which type 2 accounted for 50% of the isolates
examined. The majority of analysed strains were
classified as type 2 (Table 1). These strains
appeared to be widely disseminated during this
period in at least two university-affiliated hospi-
tals in Warsaw (data not shown), and strain B-13
was cultured upon admission from a patient
transmitted from a third tertiary-care hospital in
Warsaw. Therefore, type 2 may be circulating in
many hospitals in the region. Interestingly, type 2
did not correspond to any of the three known
widely distributed lineages (’European clones’) of
A. baumannii, although strains belonging to Euro-
pean clones I and II were also circulating in the
hospital studied.
Carbapenem resistance of A. baumannii strains
was not related to any particular molecular type,
perhaps indicating that resistance genes can be
transferred readily between different clones. An
OXA-51-type carbapenemase was detected in all
isolates investigated (including susceptible iso-
lates). These enzymes are chromosomally located,
and seem to be an intrinsic feature of virtually all
isolates of A. baumannii, but are only very weak
carbapenemases and normally have a minimal
effect on the MIC [14]. However, it has been
suggested that the presence of an insertion
sequence upstream of the structural gene for
OXA-51 may provide a promoter for the blaOXA-51
gene, which may be involved in the expression of
carbapenem resistance under certain circum-
stances [38]. Further studies are required to clarify
the importance and expression of OXA-51 in these
Polish isolates.
Of greater concern was the detection by PCR of
a VIM-type MBL gene in isolates belonging to one
of the three predominant molecular types encoun-
tered. Until recently, VIM enzymes have been
identified very rarely in A. baumannii, being rep-
resented only by VIM-2 in isolates from South
Korea [39,40], which is a country in which VIM
enzymes are known to be widespread among
members of the Enterobacteriaceae and Pseudo-
monas aeruginosa. However, unrelated strains of
Acinetobacter spp. carrying VIM-1 have now been
Table 2. Antimicrobial susceptibility of Acinetobacter baumannii isolates, grouped according to molecular type
B-1 B-14 B-19 B-2 B-5 B-6 B-7 B-8 B-9 B-11 B-12 B-16 B-18 B-20 B-24 B-3 B-10 B-13 B-15 B-17 B-21 B-22 B-23 B-4
Molecular
typea
1 1 1 2 2 2 2 2 2 2 2 2 2 2-l 2 3 3 3 3 3 3 3 3 4
Ward ICU ICU CS ICU 4B ICU ICU ICU 3B 4B ICU 3B ICU ICU 6D 4B 4D ICU 8B ICU ICU 4B 6B 6D
Antibacterial
agent
Ceftazidime I R R R R R R R R R R R R R R R R R S R R R R I
Amikacin R R R R R R R R R R R R R R R R R R S R R R R R
Gentamicin R R R R R R R R R R R R R R R R R R S R R R R R
Netilmicin R S R R S I I R R S R R S R S R S S S R R I I S
Ciprofloxacin R R R R R R I R R R R R R R R R R R S R R R R R
Imipenem R S I R I R S R R I I I R R S R R S S S S S S R
Meropenem R R R I I R R R R I I I R R S R R S S S S S S S
Ampicillin–
sulbactam
R R R S S R S S S S S S S S S R R I I R I I I S
Cefepime I R R I I I I R I I R I I R S R R I I I R R R R
Co-trimoxazole R R R R I R R R R R S R R S I R R R R R R R R R
Colistin S S S S S S S S S S S S S S S S S S S S S S S S
Cefoperazone–
sulbactam
I I I S S I S S S S S S S S S I I I I R S I I S
ICU, intensive care unit; 3B, Department of gastrointestinal surgery; 4B, Department of vascular surgery and transplantation; 6B, Department of general surgery and liver
transplantation; 8B, Department of neurosurgery; 4D, Department of haematology–oncology; 6D, Department of nephrology; CS, Department of cardiosurgery.
aMolecular type 1 belongs to the European clone I lineage, and molecular type 3 belongs to the European clone II lineage.
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identified in hospitals in Greece [41]. To date, at
least 13 variants of VIM-type MBLs have been
characterised, the genes for which are often found
as gene cassettes in class 1 integrons, which in
turn are often located on conjugative plasmids.
This is the first report of a VIM-type MBL in
A. baumannii isolates from Poland. The precise
allele present in the strains from Warsaw has not
yet been identified, but it seems likely that it has
been acquired by horizontal plasmid-mediated
transfer from resistant bacteria belonging to other
genera that are commonly present in the ICU
environment. In this respect, it is worth noting
that genes belonging to the blaVIM-1 and blaVIM-2
families have recently been detected in integrons
harboured by isolates of P. aeruginosa from var-
ious centres in Poland, as well as in a single
isolate of Acinetobacter belonging to genomic
species 3 [42]. The further spread of a VIM-type
MBL to isolates belonging to one of the wide-
spread ’epidemic’ lineages (European clone II) of
A. baumannii is a cause of great concern, and
emphasises the need for continuous vigilance and
maintenance of procedures for prevention of
nosocomial infections by healthcare workers.
Further studies are needed to evaluate possible
inter-hospital spread of resistant A. baumannii
strains in Poland.
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